drugset / Trial / NCT00493454
Ibritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent Lymphomas
NaSingle-groupOpen-labelTreatment
Summary
Primary Objective: * Overall Response Rate (ORR). Secondary Objectives: * The Duration of Response (DR) and Time to Treatment Progression (TTP) in all patients and in the responders. * Complete Responses (CR)/Complete Responses unconfirmed (CRu), and Partial Responses (PR). * Time to next anticancer therapy (TTNT).
Timeline
- Start
- 2006-04
- Primary completion
- 2011-03
- Completion
- 2011-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ibritumomab tiuxetan | Monoclonal antibody | 11.1 mbq/kg | Intravenous |
| Subject | ibritumomab tiuxetan | Monoclonal antibody | 14.8 mbq/kg | Intravenous |
| Background | Rituximab | Monoclonal antibody | 250 mg/m2 | Intravenous |